解决 1 型糖尿病β细胞替代治疗中免疫耐受问题。
Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes.
机构信息
Sean N. Parker Autoimmune Research Laboratory, University of California San Francisco, San Francisco, CA 94143, USA; Diabetes Center, University of California San Francisco, San Francisco, CA 94143, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129, USA; Sonoma Biotherapeutics, South San Francisco, CA 94080, USA.
Diabetes Center, University of California San Francisco, San Francisco, CA 94143, USA; Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
出版信息
Cell Stem Cell. 2020 Oct 1;27(4):505-507. doi: 10.1016/j.stem.2020.09.008.
Type 1 diabetes mellitus results from autoimmune destruction of pancreatic β cells. Insulin treatment is often inadequate in preventing devastating complications. Replacing β cells using stem cell-derived islets while fostering immune tolerance, exemplified in Yoshihara et al., holds the promise of a curative therapy for this disease.
1 型糖尿病由自身免疫破坏胰腺β细胞引起。胰岛素治疗常常不足以预防严重的并发症。使用干细胞衍生的胰岛来替代β细胞，同时促进免疫耐受，正如 Yoshihara 等人所展示的，为这种疾病提供了一种有希望的治愈疗法。
Zotero 插件